Drug Makers Outsourcing To China Exposed To Safety Issues
This article was originally published in PharmAsia News
Executive Summary
The move by multinational drug makers to outsource work to low-wage countries such as China is exposing the companies to the consequences of lax safety provisions. Safety issues in China already are causing concern in the U.S. FDA and in other countries that import its drugs. China is the world's largest producer of active pharmaceutical ingredients. The latest incident involves Baxter International and harmful side effects of its Heparin (heparin sodium), supplied by a Chinese company whose identity the FDA does not disclose. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.